CEVEC appoints new management team
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, today announced its new management team.
List view / Grid view
News
Kymab succeeds in revoking Regeneron’s European Patent
22 September 2014 | By Kymab
Kymab Limited announced that the European Patent Office has granted Kymab's request to entirely revoke European Patent EP1,360,287B1, owned by Regeneron Pharmaceuticals Inc...
Mary Tanner appointed to Genticel’s Supervisory Board as independently-acting member
22 September 2014 | By Andrew Lloyd & Associates
GENTICEL announces that following the Supervisory Board’s meeting held on September 11, 2014, Mary Tanner has been appointed to the board as a new independently-acting member and as Audit Committee chairman...
European Commission grants marketing authorization for Gilead’s Zydelig® (Idelalisib) for the treatment of chronic lymphocytic leukemia and follicular lymphoma
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...
Nexstim plans an Initial Public Offering on NASDAQ OMX First North
19 September 2014 | By Nexstim
Nexstim Oy announces its intention to proceed with an Initial Public Offering of Nexstim on NASDAQ OMX First North Finland and NASDAQ OMX First North Sweden...
New IDegLira (insulin degludec/liraglutide; Xultophy®) data show glycaemic improvements with increased predictability in glycaemic control within one day in people with type 2 diabetes
19 September 2014 | By Novo Nordisk
New analyses of Phase 3a IDegLira (insulin degludec /liraglutide; Xultophy®) DUAL™ study data show an early and substantial improvement in glycaemic control, and a beneficial weight profile in type 2 diabetes patients compared to insulin degludec...
Bioxodes’ antithrombotic meets development milestones – Company to launch Series A investment round to bring the product to the clinic
19 September 2014 | By Andrew Lloyd & Associates
Bioxodes SA announces that it has successfully brought its lead product, Ir-CPI, through pre-clinical development confirming its potential as the first in a new class of antithrombotic medicines...
Plegridy™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
19 September 2014 | By BIogen Idec
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY™ (peginterferon beta-1a) were maintained in adults with relapsing-remitting multiple sclerosis (RRMS) beyond the first year of the study...
Tecan offers next-generation sequencing sample preparation at the touch of a button
18 September 2014 | By kdm communications
Tecan has launched the Freedom EVO® NGS workstation to simplify next-generation sequencing (NGS) sample preparation and PCR set-up...
Detailed results from Biogen Idec and Abbvie’s pivotal phase 3 decide study further define the efficacy and safety profile of Zinbryta™
18 September 2014 | By Biogen Idec
Biogen Idec and AbbVie announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity...
Cubist announces continued global expansion with opening of International Headquarters in Zurich
18 September 2014 | By Cubist Pharmaceuticals
With resistant bacterial infections resulting in an estimated 25,000 deaths in the European Union and 23,000 deaths in the United States annually, the issues of rising antibiotic resistance and the lack of treatment options have raised alarms with world leaders...
Ergomed plc provides update on co-development partnerships
18 September 2014 | By Issued by Hume Brophy on behalf of Ergomed
Good progress with partnerships and additional clinical studies commenced...
MSD presents first Phase 3 data in Japanese patients for Omarigliptin, an investigational once-weekly DPP-4 inhibitor for Type 2 Diabetes Omarigliptin significantly reduced HbA1c levels compared to placebo
18 September 2014 | By Merck
MSD, known as Merck & Co., Inc. in the United States and Canada, announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes...
Ample room available for novel products in metastatic prostate cancer treatment market, says GlobalData Analyst
18 September 2014 | By Globaldata
Despite numerous product launches in the metastatic castration-resistant prostate cancer treatment market since 2010, ample opportunity still exists for drug developers to claim their stake in the arena...
Roche investing in Kaiseraugst
18 September 2014 | By Roche
Roche announced that it is planning to invest more than half a billion Swiss francs in buildings and infrastructure projects at Kaiseraugst...
